阿基仑赛注射液用于既往接受过不同的靶向CD19嵌合抗原受体T细胞疗法治疗的复发或难治性淋巴瘤。
Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapy.
作者信息
Chow Victor A, Gopal Ajay K, Gauthier Jordan, Tseng Yolanda D, Turtle Cameron J, Maloney David G, Shadman Mazyar
机构信息
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and.
Medical Oncology Division, Department of Medicine and.
出版信息
Blood Adv. 2020 Oct 13;4(19):4869-4872. doi: 10.1182/bloodadvances.2020002292.
Abstract
No meaningful responses were observed when axicabtagene ciloleucel was used for progression after a different CD19-directed CAR T cell. Further research is needed to understand how to sequence cell-based therapies for relapsed/refractory large B-cell lymphomas.
摘要
当在使用另一种靶向CD19的嵌合抗原受体（CAR）T细胞后疾病进展时使用axi-cabtagene ciloleucel，未观察到有意义的反应。需要进一步研究以了解如何对复发/难治性大B细胞淋巴瘤进行基于细胞疗法的排序。
相似文献
1
Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapy.
Blood Adv. 2020 Oct 13;4(19):4869-4872. doi: 10.1182/bloodadvances.2020002292.
2
Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma: Practical Implications for the Community Oncologist.
Oncologist. 2020 Jan;25(1):e138-e146. doi: 10.1634/theoncologist.2019-0395. Epub 2019 Oct 4.
3
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Lancet Oncol. 2019 Jan;20(1):31-42. doi: 10.1016/S1470-2045(18)30864-7. Epub 2018 Dec 2.
4
Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A Review.
JAMA Oncol. 2020 Feb 1;6(2):281-290. doi: 10.1001/jamaoncol.2019.3869.
5
Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma.
Ann Pharmacother. 2021 Mar;55(3):390-405. doi: 10.1177/1060028020944233. Epub 2020 Jul 22.
6
Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma.
Bone Marrow Transplant. 2021 Mar;56(3):683-685. doi: 10.1038/s41409-020-01029-4. Epub 2020 Aug 11.
7
Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.
Leuk Lymphoma. 2018 Aug;59(8):1785-1796. doi: 10.1080/10428194.2017.1387905. Epub 2017 Oct 23.
8
Safety of axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma in an elderly intercity population.
Bone Marrow Transplant. 2021 Jul;56(7):1761-1763. doi: 10.1038/s41409-021-01280-3. Epub 2021 Apr 12.
9
Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis.
J Hematol Oncol. 2020 Jan 3;13(1):1. doi: 10.1186/s13045-019-0838-y.
10
[New European approvals: Tisagenlecleucel and Axicabtagene ciloleucel CAR-T cells - Follicular lymphoma after at least two and three prior lines of therapy].
Bull Cancer. 2022 Nov;109(11):1106-1108. doi: 10.1016/j.bulcan.2022.07.003. Epub 2022 Sep 7.
引用本文的文献
1
Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure.
Transplant Cell Ther. 2023 Sep;29(9):574.e1-574.e10. doi: 10.1016/j.jtct.2023.06.019. Epub 2023 Jun 30.
2
Improving CAR T-Cell Persistence.
Int J Mol Sci. 2021 Oct 7;22(19):10828. doi: 10.3390/ijms221910828.
3
Anti-CD19 CAR T-cell therapy remission despite prior anti-CD19 antibody Tafasitamab in relapsed/refractory DLBCL.
Leuk Res Rep. 2021 Jul 14;16:100260. doi: 10.1016/j.lrr.2021.100260. eCollection 2021.
4
CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies.
J Hematol Oncol. 2021 Feb 16;14(1):26. doi: 10.1186/s13045-021-01044-y.
5
Current Immunotherapy Approaches in Non-Hodgkin Lymphomas.
Vaccines (Basel). 2020 Nov 27;8(4):708. doi: 10.3390/vaccines8040708.
本文引用的文献
1
Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy.
Am J Hematol. 2019 Aug;94(8):E209-E213. doi: 10.1002/ajh.25505. Epub 2019 May 21.
2
The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.
Blood. 2019 Apr 25;133(17):1876-1887. doi: 10.1182/blood-2018-11-887067. Epub 2019 Feb 19.
3
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1.
4
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
N Engl J Med. 2017 Dec 28;377(26):2531-2544. doi: 10.1056/NEJMoa1707447. Epub 2017 Dec 10.
5
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.
J Clin Oncol. 2017 Sep 10;35(26):3010-3020. doi: 10.1200/JCO.2017.72.8519. Epub 2017 Jul 17.
Zotero 插件